Last reviewed · How we verify
triazolam tablets
At a glance
| Generic name | triazolam tablets |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal (NA)
- Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient (NA)
- A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects (PHASE1)
- Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption (PHASE1)
- Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- triazolam tablets CI brief — competitive landscape report
- triazolam tablets updates RSS · CI watch RSS
- Pfizer portfolio CI